BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Zheng Q, Kang W, Yu C. Long non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell proliferation, migration and invasion through miR-93-5p/PDCD4 pathway. Clinics and Research in Hepatology and Gastroenterology 2019;43:436-45. [DOI: 10.1016/j.clinre.2018.11.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
2 Xia HB, Wang HJ, Fu LQ, Wang SB, Li L, Ru GQ, He XL, Tong XM, Mou XZ, Huang DS. Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2018;16:3681-9. [PMID: 30127978 DOI: 10.3892/ol.2018.9073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Jin C, Li Y, Su Y, Guo Z, Wang X, Wang S, Zhang F, Zhang Z, Shao J, Zheng S. Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26. Cell Death Dis 2020;11:844. [PMID: 33041323 DOI: 10.1038/s41419-020-03048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang X, Wu B, Zhong Z. Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells. Oncol Lett 2018;16:585-93. [PMID: 29928445 DOI: 10.3892/ol.2018.8633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kong Q, Li W, Hu P, Zeng H, Pan Y, Zhou T, Hu K. The expression status of ZIC2 is an independent prognostic marker of hepatocellular carcinoma. Liver Research 2020;4:40-6. [DOI: 10.1016/j.livres.2020.02.001] [Reference Citation Analysis]
6 Gao C. Molecular pathological epidemiology of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2018; 26(9): 557-563 [DOI: 10.11569/wcjd.v26.i9.557] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Yu J, Wu ZZ, Li T, Xu Y, Zhao YC, Zhang BL, Tian H. Effectiveness of surgical resection for complicated liver cancer and its influencing factors: A retrospective study. World J Clin Cases 2020; 8(4): 736-742 [PMID: 32149057 DOI: 10.12998/wjcc.v8.i4.736] [Reference Citation Analysis]
8 Zhang XW, Li QH, Xu ZD, Dou JJ. STAT1-induced regulation of lncRNA ZFPM2-AS1 predicts poor prognosis and contributes to hepatocellular carcinoma progression via the miR-653/GOLM1 axis. Cell Death Dis 2021;12:31. [PMID: 33414427 DOI: 10.1038/s41419-020-03300-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zheng H, Zhang G, Zhang L, Wang Q, Li H, Han Y, Xie L, Yan Z, Li Y, An Y, Dong H, Zhu W, Guo X. Comprehensive Review of Web Servers and Bioinformatics Tools for Cancer Prognosis Analysis. Front Oncol 2020;10:68. [PMID: 32117725 DOI: 10.3389/fonc.2020.00068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
10 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
11 Gao C, Zhang H, Zhang WS, Fang L. Expression and Significance of Insulin Receptor Substrate 1 in Human Hepatocellular Carcinoma. Dis Markers 2020;2020:7174062. [PMID: 32695243 DOI: 10.1155/2020/7174062] [Reference Citation Analysis]
12 Gilani SNS, Mehta A, Garcia-Fadrique A, Rowaiye B, Jenei V, Dayal S, Chandrakumaran K, Carr N, Mohamed F, Cecil T, Moran B. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperthermia 2018;34:578-84. [PMID: 29431036 DOI: 10.1080/02656736.2018.1434902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
13 Zhou L, Wang H, Yi J, Yang B, Li M, He D, Yang W, Zhang Y, Ni H. Anti-tumor properties of anthocyanins from Lonicera caerulea 'Beilei' fruit on human hepatocellular carcinoma: In vitro and in vivo study. Biomed Pharmacother 2018;104:520-9. [PMID: 29800916 DOI: 10.1016/j.biopha.2018.05.057] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
14 Sacco R, Granito A, Bargellini I, Zolfino T, Saitta C, Marzi L, Tapete G, Bresci G, Marinelli S, Tovoli F, Attardo S, Rossi M, Urbani L, Marchi S, Buccianti P, Cabibbo G. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol 2018;14:3049-58. [PMID: 30091371 DOI: 10.2217/fon-2018-0281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Qiao G, Xu H, Li C, Li X, Farooqi AA, Zhao Y, Liu X, Liu M, Stagos D, Lin X. Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3060. [PMID: 30301274 DOI: 10.3390/ijms19103060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ceballos MP, Angel A, Delprato CB, Livore VI, Ferretti AC, Lucci A, Comanzo CG, Alvarez ML, Quiroga AD, Mottino AD, Carrillo MC. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. Eur J Pharmacol 2021;892:173736. [PMID: 33220273 DOI: 10.1016/j.ejphar.2020.173736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chen W, Ou M, Tang D, Dai Y, Du W. Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma. J Immunol Res 2020;2020:5494858. [PMID: 32211443 DOI: 10.1155/2020/5494858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
18 Dong XD, Liu YN, Zhao Y, Liu AJ, Ji HY, Yu J. Structural characterization of a water-soluble polysaccharide from Angelica dahurica and its antitumor activity in H22 tumor-bearing mice. Int J Biol Macromol 2021;193:219-27. [PMID: 34688677 DOI: 10.1016/j.ijbiomac.2021.10.110] [Reference Citation Analysis]
19 Wang X, Chen D, Chen B. The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas. Acad Radiol 2020;27:1720-6. [PMID: 29941397 DOI: 10.1016/j.acra.2018.04.021] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68:1065-75. [PMID: 30108162 DOI: 10.1136/gutjnl-2018-316408] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 34.3] [Reference Citation Analysis]
21 Hernández-Bule ML, Martínez MA, Trillo MÁ, Martínez L, Toledano-Macías E, Úbeda A. Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current. Oncol Lett 2021;22:807. [PMID: 34630714 DOI: 10.3892/ol.2021.13068] [Reference Citation Analysis]
22 Liu XF, Thin KZ, Ming XL, Shuo-Li, Ping-Luo, Man-Zhu, Li ND, Tu JC. Small Nucleolar RNA Host Gene 18 Acts as a Tumor Suppressor and a Diagnostic Indicator in Hepatocellular Carcinoma. Technol Cancer Res Treat 2018;17:1533033818794494. [PMID: 30126319 DOI: 10.1177/1533033818794494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
23 He X, Li M, Yu H, Liu G, Wang N, Yin C, Tu Q, Narla G, Tao Y, Cheng S, Yin H. Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex. PLoS Biol 2020;18:e3000803. [PMID: 33275593 DOI: 10.1371/journal.pbio.3000803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sin STK, Li Y, Liu M, Yuan YF, Ma S, Guan XY. Down-regulation of TROP-2 Predicts Poor Prognosis of Hepatocellular Carcinoma Patients. Hepatol Commun 2018;2:1408-14. [PMID: 30411086 DOI: 10.1002/hep4.1242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chen Y, Chen X, Ding X, Wang Y. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway. Mol Med Rep 2019;20:3317-25. [PMID: 31432165 DOI: 10.3892/mmr.2019.10562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Liu H, Li J, Yuan W, Hao S, Wang M, Wang F, Xuan H. Bioactive components and mechanisms of poplar propolis in inhibiting proliferation of human hepatocellular carcinoma HepG2 cells. Biomed Pharmacother 2021;144:112364. [PMID: 34700230 DOI: 10.1016/j.biopha.2021.112364] [Reference Citation Analysis]
28 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
29 Zhu Y, Li C, Lin X, Sun J, Cheng Y. [Effect of Atractylodes macrocephala polysaccharide on proliferation and invasion of hepatocellular carcinoma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:1180-5. [PMID: 31801717 DOI: 10.12122/j.issn.1673-4254.2019.10.08] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Zhao L, Zhang Y, Zhang Y. Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis. J Cell Physiol 2018;233:6661-70. [PMID: 29319182 DOI: 10.1002/jcp.26446] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]